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Purpose—Extracellular proteins are easily accessible, which presents a sub-proteome of
molecular targets that have high diagnostic and therapeutic potential. Efforts have been made to
catalogue the cardiac extracellular matridome and analyze the topology of identified proteins for
the design of therapeutic targets. Although many bioinformatics tools have been developed to
predict protein topology, topology has been experimentally validated for only a very small portion
of membrane proteins. The aim of this study was to use a glycoproteomics and mass spectrometry
approach to identify glycoproteins in the extracellular matridome of the infarcted LV and provide
experimental evidence for topological determination.
Experimental design—Glycoproteomics analysis was performed on eight biological replicates
of day 7 post-MI samples from wild type mice using solid-phase extraction of glycopeptides,
followed by mass spectrometric identification of N-linked glycosylation sites for topology
assessment.
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Results—We identified hundreds of glycoproteins and the identified N-glycosylation sites
provide novel information on the correct topology for membrane proteins present in the infarct
setting.
Conclusions and clinical relevance—Our data provides the foundation for future studies of
the LV infarct extracellular matridome, which may facilitate the discovery of drug targets and
biomarkers.
Keywords
Extracellular matridome; glycoprotein; membrane orientation; matrix metalloproteinase;
proteomics; myocardial infarction; left ventricle

1 Introduction
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The extracellular matridome consists of all proteins expressed outside of cells, including
transmembrane proteins, cell surface proteins, extracellular matrix (ECM) proteins, and
secreted proteins [1]. The composition includes receptors, growth factors, cytokines,
chemokines, hormones, enzymes, and fibrillar components [2]. The cardiac extracellular
proteome provides the left ventricle (LV) with mechanical support, coordinates the signal
transduction capabilities, and regulates cell functions by modifying biological processes [3].
Myocardial infarction (MI) is associated with extensive extracellular protein turnover as old
ECM is replaced by an infarct scar that is primarily composed of ECM. MI is a highly
prevalent cardiovascular disease, with over 1.5 million new patients diagnosed each year in
the U.S. [4]. LV remodeling following MI depends on the balance between ECM
degradation and deposition, as too much degradation can lead to LV aneurysms or rupture
and too much deposition can lead to a stiff LV that provides a substrate for the development
of heart failure [5]. Matrix metalloproteinase-9 (MMP-9) is a member of the family of
enzymes that break down ECM and has been shown to play a critical role in LV remodeling
post-MI [6, 7].
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Knowledge of protein structure provides crucial information for understanding protein
function, including information on location and availability for post-translational
modification that is necessary for selecting optimal antigen sites and identifying drug
targets. A common feature for optimal antigens and drug targets is easy accessibility,
making extracellular protein analysis highly relevant to drug development for LV
remodeling post-MI [8]. Therefore, efforts have been made to determine the spatial
orientation of target proteins. In addition to the traditional methods for topology evaluation,
membrane protein side accessibility is becoming a tool to evaluate protein orientation.
Examples of this concept include N-glycosylation sites, antibody epitopes, iodinatable sites,
and proteolytic sites [8]. The reason N-glycosylation sites can be used for topology
evaluation is based on the fact N-linked glycosylation occurs only in extracellular domains
of membrane proteins [9].
The goal of this study was to examine the geographic location of proteins in the LV infarct
region, focusing on the extracellular matridome. Glycoproteomic analysis was performed on
eight biological replicates of day 7 post-MI samples from wild type mice using solid-phase
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extraction of glycopeptides, followed by mass spectrometric identification of N-linked
glycosylation sites for topology assessment [10, 11]. The logic of this examination was
based on the concept that extracellular proteins are frequently N-glycosylated [12–14];
therefore, preferential isolation of N-linked glycoproteins would greatly enrich for the
extracellular matridome [1, 13, 15]. In the present study, we identified 1352 N-linked
glycosylation sites, and 56% of them were from membrane proteins proteins. Since
membrane N-glycans always face the extracellular space, the identification of these
glycosites provides topological information and helps to determine the protein orientation.

2 Materials and methods
2.1 Mice
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C57BL/6J male and female mice, 3–6 months of age, were used in this study (n=8, 4 male
and 4 female). Mice were kept in a light-controlled environment with a 12:12 hour lightdark cycle and given free access to standard mice chow and water. All animal procedures
were approved by the Institutional Animal Care and Use Committee at the University of
Texas Health Science Center at San Antonio and the University of Mississippi Medical
Center in accordance with the “Guide for the Care and Use of Laboratory Animals”. The
mice underwent permanent coronary artery ligation surgery, to produce myocardial
infarction, as described previously [16, 17]. At day 7 post-MI, the mice were sacrificed.
2.2 Tissue samples and protein extraction
The infarct region of the LV was collected at 7 days post-MI as described previously [17],
and the LV tissue was homogenized first in phosphate buffered saline (PBS; 16 μL per mg
LV wet weight) with 1x protease inhibitors (Roche, Basel, Switzerland) and centrifuged to
remove the soluble fraction. The insoluble pellet was homogenized in Reagent 4 (16 μL per
mg LV wet weight; Sigma, St. Louis, MO) with 1x protease inhibitors [18]. Because the
insoluble fraction is enriched for ECM, we used that fraction for the glycoproteomic
analysis.
2.3 Trypsin digestion
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Total protein from the insoluble fraction (1 mg) was denatured and reduced by adding 8 M
urea and 12 mM Tris (2-carboxyethyl) phosphine hydrochloride (TCEP) in 1 M ammonium
bicarbonate and incubating at 37°C for 1 h. The samples were alkylated with 16 mM
iodoacetamide at room temperature in the dark for 30 min. The samples were diluted 5-fold
with water prior to the addition of trypsin (Promega, Madison, WI), which was added at a
ratio of 1:50 (w/w, enzyme: protein). The samples were digested at 37°C overnight with
gentle shaking. The samples were centrifuged to remove precipitate. Peptides were cleaned
by Sep-Pak Vac C18 cartridge (Waters, Milford, MA). Peptide concentration was
determined by BCA assay (Thermo Fisher Scientific, Rochford, IL).
2.4 N-Linked Glycopeptide Capture

N-linked glycopeptides were isolated from the tryptic peptides using the solid phase
extraction of glycopeptides (SPEG) method previously reported [10, 11]. Briefly, 0.8 mg of
peptides was oxidized by 10 mM sodium periodate (Bio-Rad, Hercules, CA) at room
Proteomics Clin Appl. Author manuscript; available in PMC 2015 August 01.
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temperature for 1 h. Glycopeptides were covalently conjugated to a solid support via
hydrazide chemistry (Bio-Rad, Hercules, CA), with incubation at room temperature
overnight. The hydrazide beads were washed with 1.5 M NaCl, and water prior to release of
formerly N-linked glycopeptides from solid support by PNGase F (New England Biolabs,
Ipswich, MA) at 37°C overnight. The eluent was purified by Sep-Pak Vac C18 cartridge
(Waters, Milford, MA) and re-suspended in 20 μL of 0.4% acetic acid.
2.5 Mass spectrometry analysis
The peptides were analyzed by LC-MS/MS using a Q Exactive (ThermoFisher, Waltham,
MA) coupled with a 15 cm × 75 μm C18 column (5 μm particles with 100 angstrom pore
size). A nano UPLC at 300 nL/min with a 90 min linear acetonitrile gradient (from 5–35% B
over 90 min; A = 0.2% formic acid in water, B = 0.2% formic acid in 90% acetonitrile) was
used. A top 20 data dependent MS/MS with exclusion for 25 s was set. The samples were
run with HCD fragmentation at normalized collision energy of 30 and an isolation width of
2 m/z. A lock mass of the polysiloxane peak at 371.10123 was used to correct the mass in
MS and MS/MS. Target values in MS were 1e6 ions at a resolution setting of 70,000 and in
MS2 1e5 ions at a resolution setting of 17,500.
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MS/MS spectra were searched with SEQUEST using Proteome Discoverer (version 1.3;
Thermo Fisher) against the mouse IPI database (version 3.87) containing 59,534 sequences.
For this database search, the precursor mass tolerance and fragment mass tolerance were set
at 15 ppm and 0.05 Da, respectively. Trypsin was specified as the protease. The fixed
modification was set as carbamidomethylation (C), and other modifications were set as
flexible modification as follows: deamidation (N) and oxidation (M). Full-tryptic end and
two missed cleavage sites were allowed. A decoy version of the IPI mouse database was
used to estimate peptide and protein false discovery rate. The False Discovery Rate was set
at 0.01 to eliminate low-probability protein identifications.
2.6 Protein classification
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Signal peptides were predicted using SignalP 4.1 [19]. Transmembrane (TM) helices were
predicted using the TMHMM program (version 2.0; CBS prediction servers), which predicts
protein topology and the number of TM helices [20]. Information from SignalP and
TMHMM were combined to classify proteins into one of the following 6 categories: (i)
secreted proteins that contain predicted cleavable signal peptides and no predicted TM
segments; (ii) single TM type I proteins that contain predicted single TM helix with an
extracellular (or luminal) N-terminus; (iii) single TM type II proteins that contain predicted
single TM helix with an extracellular (or luminal) C-terminus; (iv) multiple TM proteins that
contain multiple TM helices; or (v) ambiguous proteins [21].

3 Results
3.1 Extracellular matridome of cardiac tissue
To profile the extracellular matridome of post-MI LV tissue, the infarct region was
analyzed. Since extracellular proteins are more likely to be glycosylated compared to
intracellular proteins [8], the glycopeptide capture method was used to enrich for
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extracellular proteins [10, 11]. Of the identified peptides, 95.6% were de-glycosylated and
had N-linked glycosylation motif (NXS/T, where X is any amino acid except proline). We
also determined the extent of spontaneous deamidation on Asn residues in the Nglycosylation motif by profiling the un-conjugated fraction of hydrazide beads with or
without PNGase F treatment [22]. The rate of spontaneous deamidation was 1.5% in our
sample sets. The deamidated peptides identified in this negative control were not included in
the identification list (Supplementary Table S1).
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A total of 1352 unique N-linked glycosylation sites were identified, with a 1% false
discovery rate (FDR), and these sites represented 694 unique glycoproteins (Supplemental
Table S1). A unique glycosylation site was defined as a peptide containing a unique
glycosylation motif, regardless of the length of the peptide and other modification of amino
acid other than on asparagine in the motif. As summarized in Figure 1A, 406 proteins (59%)
were identified as having one unique glycosite, whereas 288 (41%) were identified as
having two or more unique glycosites. The majority of single-glycosites (80%) were
identified more than two times (either in multiple identifications of the same peptide
sequence with varying charge states or in different peptides). For the single-glycosite
peptides only identified once, the annotated MS/MS spectra are provided in Supplemental
Table S2. Many ECM proteins were identified with multiple peptides, such as collagens,
fibronectin, and laminins (Supplemental Table S2).
The prevalence of identified glycopeptides in eight biological replicates is illustrated in
Figure 1B. A total of 907 glycosites (67%) were identified in at least 4 biological replicates,
whereas 200 glycosites (15%) were only identified in one of the biological replicates.
Notably, 486 glycosites (36%) were identified from all eight samples. This large overlap
indicates that our data were highly consistent in biological replicates, implicating good
coverage of the N-glycoproteome in the mouse LV infarct region.
3.2 Functional analysis and KEGG pathway analysis of identified glycoproteins
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To obtain an overview of the molecular functions and associated pathways, the identified
glycoproteins were analyzed using David bioinformatics tools (6.7) [23, 24]. With 1% FDR,
many functions related to extracellular activities were significantly enriched (p < 0.01),
including calcium ion binding, exopeptidase activity, endopeptidase inhibitor activity,
peptidase activity, carboxypeptidase activity, ECM structural constituent,
metalloexopeptidase activity, and metallocarboxypeptidase activity (Table 1 and
Supplemental Table S3). KEGG pathway analysis using DAVID revealed similar results
[25]. The N-glycoproteome enriched the pathways of ECM-receptor interaction, cell
adhesion molecules, arrhythmogenic right ventricular cardiomyopathy, hypertrophic
cardiomyopathy, and dilated cardiomyopathy (Table 1 and Supplemental Table S3). These
results indicate that the N-glycoproteome of the LV infarct region has important myocardial
functions, and the identified extracellular proteome contains a large number of cardiac
specific glycoproteins.
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Based on the information from SignalP and TMHMM, the proteins were classified into one
of five categories: secreted, single transmembrane protein (TM) type I, single TM type II,
multiple TM, or ambiguous [21]. Of 694 identified proteins, 388 (56%) were TM proteins
including single TM type I, type II, and multiple TM (Figure 1C). The identification of Nlinked glycosylation site provided topological information for the transmembrane proteins,
since N-linked glycosylation only occurs in extracellular domains of plasma membrane
proteins. Because the orientation of single TM protein determines the protein type, this
information is important to corroborate the orientation prediction of single TM proteins. Our
study identified 153 single TM type I proteins and 107 single TM type II proteins based on
the prediction using TMHMM. The single TM type I proteins have extracellular (or luminal)
N-terminus, while the single TM type II proteins have extracellular (or luminal) C-terminus.
The identified N-glycosites matched with the TMHMM predicted single TM protein type for
252 of the 260 proteins (Supplementary Table S4). The remaining 8 single TM proteins had
identified N-glycosites that TMHMM predicted to be cytoplasmic domains (Supplementary
Table S4). For these 8 proteins, we checked the topology prediction in Swiss-Prot, and
found that our results matched Swiss-Prot prediction (which was of TMHMM prediction)
for 7 of the 8 proteins. The final protein was not recorded in Swiss-Prot.
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Many integrins were identified in the most enriched KEGG pathway, ECM-receptor
interaction. They are the major adhesion receptor for many ECM proteins, and their primary
role is to link ECM to the intracellular signaling network [26]. Therefore, it is very
important to determine their topology in order to fully understand the signaling interactions.
Fourteen integrins are predicted as single transmembrane proteins. Table 2 shows the
predicted topology of these integrins, how many N-glycosites are predicted in the
extracellular domain, and how many of the predicted N-glycosites identified in this study are
in the extracellular domain. The identified glycosylation sites were all in the predicted
extracellular domains, supporting the topology prediction. The β1 Integrin is further
illustrated in Figure 2. The β1 Integrin has fourteen predicted N-linked glycosites, which are
located in the potential extracellular domain (Figure 2). However, out of fourteen predicted
N-linked glycosites in β1 integrin, only four have supporting experimental evidence
according to Swiss-prot (highlighted in green). Our study identified four novel N-glycosites
for β1 Integrin (namely, N212, N406, N481, N520, highlighted in yellow) in addition to one
of the four N-glycosites recorded in Swiss-prot (Figure 2). These glycosites confirm the
extracellular domain prediction of β1 integrin.

4 Discussion
This study employed a glycoproteomic analysis followed by mass spectrometry and a
topology bioinformatic assessment to profile the extracellular matridome of the LV infarct
region. The most significant findings were: 1) 1352 unique N-linked glycosylation sites
(representing 694 unique glycoprotein groups) were identified, with the majority (77%)
being membrane proteins and secreted proteins; 2) the extracellular proteins identified
included collagens, fibronectin, and laminins. These proteins were highly prevalent in the
LV infarct; and 3) analysis of N-linked glycosites provides experimental evidence of
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membrane protein orientation. Out of 260 single TM proteins, the N-glycopeptides
identified in the present study confirmed 259 proteins for the topology prediction using
TMHMM or Swiss-Prot. TMHMM and Swiss-Prot had opposite topology predictions for
seven proteins. Combined, these results provide the first glycoproteomic analysis of the
extracellular matridom of the LV infarct region and validate the assumption that
extracellular proteins are greatly enriched by the glycoprotein isolation approach used.
These results also provide useful geographic information on membrane proteins, which will
help in mechanistic and drug discovery studies, particularly for the proteins having
controversial topology prediction.
Using a glycoproteomic approach to profile the extracellular matridome allows enrichment
for extracellular proteins, targeting proteins with important signaling roles. In the functional
analysis and pathway annotation of the identified proteins, functions related to extracellular
proteins and cardiac signaling pathways were significantly enriched. For example, MMP-9
was identified as a central player, and roles for this metalloproteinase in the post-MI setting
have been well documented [7, 27–29].
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Using the N-linked glycosylation site analysis provided in vivo topologic evidence that has
not been previously available. Zielinska et al demonstrated that glycosylation sites of
membrane proteins always orient toward the extracellular space [30]. Gundry and coworkers found one glycoprotein transmembrane orientation was inconsistent with SwissProt annotation using glycoproteomic analysis, providing complementary information to
correct the protein orientation prediction [9]. Rossi et al studied the membrane-bound form
of complement protein C9 using glycosylation mapping, anti-peptide antibody binding, and
disulfide modification analyses [31]. By deleting two N-glycosites and introducing new Nglycosites, the authors determined the glycosylation required for human C9 activity and its
membrane anchoring, which shows that the glycosite identification is a useful tool for
protein orientation assignment. The current study identified 1352 unique N-linked
glycosylation sites, providing new topologic information (Table 2 and Supplemental table
S1). For β1 integrin, there were fourteen predicted N-linked glycosites, but only four of them
(namely, N363, N366, N376, and N669) were identified previously according to Swiss-prot.
In addition, these glycosites (N363, N366, and N376) are very close to each other, which is
not good for supporting the large region (728 aa) of the extracelluar domain prediction. Our
study identified four novel N-glycosites for β1 Integrin (namely N212, N406, N481, and
N520) in addition to one of four N-glycosites (N669) recorded in Swiss-prot. These four
novel glycosites were also recently identified by other groups [32, 33]. These five sites were
distributed throughout the predicted extracellular domain, which provides supporting
evidence for this section being the extracellular domain region of β1 integrin.
In the present data, 406 (59%) glycoproteins were identified by one unique glycosite,
whereas 288 (41%) were identified by two or more unique glycosites. There are several
possible reasons for a single identification. The first reason is that there really is only one
potential N-glycosite in the protein. Out of the 406 proteins identified with one unique
glycosite, 52 (12.8%) had only one single predicted glycosite, indicating that this reason
accounted for a minority of the proteins. A second reason is that the peptide length of some
glycopeptides may not be suitable for mass spectrometry analysis. Usually, a peptide length
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of 7–35 residues is most suitable for mass spectrometry sequencing technology [34]. A third
reason is that some peptides may not be suitable for identification due to poor ionization and
fragmentation. A fourth reason is the random sampling issue of mass spectrometry, which
basically means that false negatives can occur. Our results indicate that all of the above
reasons likely contribute to the results. To assess the quality of identification, the single
identified glycosites were counted for the number of peptide-spectra matching. We found
that the majority of single glycosites (80%) were identified more than two times (either in
multiple identification of the same peptide sequence or in different glycopeptides),
indicating the majority of the glycopeptide identification was reliable.
In conclusion, this study identified a large number of extracellular proteins in the LV infarct.
The information of experimentally identified N-glycosites provides in vivo experimental
evidence for topology prediction. Our data provides the foundation for future studies of the
LV infarct extracellular matridome, which may facilitate the discovery of drug targets and
biomarkers.
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Refer to Web version on PubMed Central for supplementary material.

Acknowledgments
We acknowledge support from AHA for POST14350034 and NIH/NHLBI T32 HL074464 to KYD-P, from NIH
R00AT006704 to GVH, from Johns Hopkins Proteomics Center (N01-HV-00240) and Programs of Excellence in
Glycosicences (PEG, P01HL107153) to HZ, from NIH/NHLBI HHSN 268201000036C (N01-HV-00244) for the
San Antonio Cardiovascular Proteomics Center and R01 HL075360, HL051971, and GM104357 and from the
Biomedical Laboratory Research and Development Service of the Veterans Affairs Office of Research and
Development Award 5I01BX000505 to MLL.

Abbreviations

NIH-PA Author Manuscript

ECM

extracellular matrix

LV

left ventricle

TM

transmembrane

PNGase F

Peptide-N-Glycosidase F

References
1. Tian Y, Kelly-Spratt KS, Kemp CJ, Zhang H. Mapping tissue-specific expression of extracellular
proteins using systematic glycoproteomic analysis of different mouse tissues. J Proteome Res. 2010;
9:5837–5847. [PubMed: 20828161]
2. Didangelos A, Yin X, Mandal K, Baumert M, et al. Proteomics characterization of extracellular
space components in the human aorta. Mol Cell Proteomics. 2010; 9:2048–2062. [PubMed:
20551380]
3. Jourdan-Lesaux C, Zhang J, Lindsey ML. Extracellular matrix roles during cardiac repair. Life Sci.
87:391–400. [PubMed: 20670633]
4. Frantz S, Bauersachs J, Ertl G. Post-infarct remodelling: contribution of wound healing and
inflammation. Cardiovasc Res. 2009; 81:474–481. [PubMed: 18977766]

Proteomics Clin Appl. Author manuscript; available in PMC 2015 August 01.

Tian et al.

Page 9

NIH-PA Author Manuscript
NIH-PA Author Manuscript
NIH-PA Author Manuscript

5. Zamilpa R, Lindsey ML. Extracellular matrix turnover and signaling during cardiac remodeling
following MI: causes and consequences. J Mol Cell Cardiol. 48:558–563. [PubMed: 19559709]
6. Kelly D, Cockerill G, Ng LL, Thompson M, et al. Plasma matrix metalloproteinase-9 and left
ventricular remodelling after acute myocardial infarction in man: a prospective cohort study. Eur
Heart J. 2007; 28:711–718. [PubMed: 17339265]
7. Lindsey ML, Escobar GP, Dobrucki LW, Goshorn DK, et al. Matrix metalloproteinase-9 gene
deletion facilitates angiogenesis after myocardial infarction. Am J Physiol Heart Circ Physiol. 2006;
290:H232–239. [PubMed: 16126817]
8. van Geest M, Lolkema JS. Membrane topology and insertion of membrane proteins: search for
topogenic signals. Microbiol Mol Biol Rev. 2000; 64:13–33. [PubMed: 10704472]
9. Gundry RL, Raginski K, Tarasova Y, Tchernyshyov I, et al. The mouse C2C12 myoblast cell
surface N-linked glycoproteome: identification, glycosite occupancy, and membrane orientation.
Mol Cell Proteomics. 2009; 8:2555–2569. [PubMed: 19656770]
10. Zhang H, Li XJ, Martin DB, Aebersold R. Identification and quantification of N-linked
glycoproteins using hydrazide chemistry, stable isotope labeling and mass spectrometry. Nat
Biotechnol. 2003; 21:660–666. [PubMed: 12754519]
11. Tian Y, Zhou Y, Elliott S, Aebersold R, Zhang H. Solid-phase extraction of N-linked
glycopeptides. Nat Protoc. 2007; 2:334–339. [PubMed: 17406594]
12. Roth J. Protein N-glycosylation along the secretory pathway: relationship to organelle topography
and function, protein quality control, and cell interactions. Chem Rev. 2002; 102:285–303.
[PubMed: 11841244]
13. Cordwell SJ, Thingholm TE. Technologies for plasma membrane proteomics. Proteomics. 2010;
10:611–627. [PubMed: 19834916]
14. McDonald CA, Yang JY, Marathe V, Yen TY, Macher BA. Combining results from lectin affinity
chromatography and glycocapture approaches substantially improves the coverage of the
glycoproteome. Mol Cell Proteomics. 2009; 8:287–301. [PubMed: 18923192]
15. Sun B, Hood L. Protein-Centric N-Glycoproteomics Analysis of Membrane and Plasma Membrane
Proteins. Journal of proteome research. 2014
16. Lindsey ML, Escobar GP, Dobrucki LW, Goshorn DK, et al. Matrix metalloproteinase-9 gene
deletion facilitates angiogenesis after myocardial infarction. Am J Physiol Heart Circ Physiol.
2006; 290:H232–239. [PubMed: 16126817]
17. Zamilpa R, Zhang J, Chiao YA, Bras LE, et al. Cardiac wound healing post-myocardial infarction:
a novel method to target extracellular matrix remodeling in the left ventricle. Methods Mol Biol.
2013; 1037:313–324. [PubMed: 24029944]
18. de Castro Bras LE, Ramirez TA, DeLeon-Pennell KY, Chiao YA, et al. Texas 3-step
decellularization protocol: looking at the cardiac extracellular matrix. J Proteomics. 2013; 86:43–
52. [PubMed: 23681174]
19. Petersen TN, Brunak S, von Heijne G, Nielsen H. SignalP 4.0: discriminating signal peptides from
transmembrane regions. Nat Methods. 2011; 8:785–786. [PubMed: 21959131]
20. Krogh A, Larsson B, von Heijne G, Sonnhammer EL. Predicting transmembrane protein topology
with a hidden Markov model: application to complete genomes. J Mol Biol. 2001; 305:567–580.
[PubMed: 11152613]
21. Chou KC, Elrod DW. Prediction of membrane protein types and subcellular locations. Proteins.
1999; 34:137–153. [PubMed: 10336379]
22. Palmisano G, Melo-Braga MN, Engholm-Keller K, Parker BL, Larsen MR. Chemical deamidation:
a common pitfall in large-scale N-linked glycoproteomic mass spectrometry-based analyses. J
Proteome Res. 2012; 11:1949–1957. [PubMed: 22256963]
23. Huang da W, Sherman BT, Lempicki RA. Bioinformatics enrichment tools: paths toward the
comprehensive functional analysis of large gene lists. Nucleic Acids Res. 2009; 37:1–13.
[PubMed: 19033363]
24. Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists
using DAVID bioinformatics resources. Nat Protoc. 2009; 4:44–57. [PubMed: 19131956]
25. Kanehisa M, Goto S. KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 2000;
28:27–30. [PubMed: 10592173]
Proteomics Clin Appl. Author manuscript; available in PMC 2015 August 01.

Tian et al.

Page 10

NIH-PA Author Manuscript
NIH-PA Author Manuscript

26. Pentassuglia L, Sawyer DB. ErbB/integrin signaling interactions in regulation of myocardial cellcell and cell-matrix interactions. Biochim Biophys Acta. 2013; 1833:909–916. [PubMed:
23261977]
27. Halade GV, Jin YF, Lindsey ML. Matrix metalloproteinase (MMP)-9: a proximal biomarker for
cardiac remodeling and a distal biomarker for inflammation. Pharmacol Ther. 2013; 139:32–40.
[PubMed: 23562601]
28. Yabluchanskiy A, Ma Y, Iyer RP, Hall ME, Lindsey ML. Matrix metalloproteinase-9: Many
shades of function in cardiovascular disease. Physiology (Bethesda). 2013; 28:391–403. [PubMed:
24186934]
29. de Castro Bras LE, Cates CA, Deleon-Pennell KY, Ma Y, et al. Citrate Synthase is a Novel In
Vivo Matrix Metalloproteinase-9 Substrate that Regulates Mitochondrial Function in the PostMyocardial Infarction Left Ventricle. Antioxid Redox Signal. 2014
30. Zielinska DF, Gnad F, Wisniewski JR, Mann M. Precision mapping of an in vivo N-glycoproteome
reveals rigid topological and sequence constraints. Cell. 2010; 141:897–907. [PubMed: 20510933]
31. Rossi V, Wang Y, Esser AF. Topology of the membrane-bound form of complement protein C9
probed by glycosylation mapping, anti-peptide antibody binding, and disulfide modification. Mol
Immunol. 2010; 47:1553–1560. [PubMed: 20153530]
32. Kaji H, Shikanai T, Sasaki-Sawa A, Wen H, et al. Large-scale identification of N-glycosylated
proteins of mouse tissues and construction of a glycoprotein database, GlycoProtDB. Journal of
proteome research. 2012; 11:4553–4566. [PubMed: 22823882]
33. Gnad F, Gunawardena J, Mann M. PHOSIDA 2011: the posttranslational modification database.
Nucleic acids research. 2011; 39:D253–260. [PubMed: 21081558]
34. Swaney DL, Wenger CD, Coon JJ. Value of using multiple proteases for large-scale mass
spectrometry-based proteomics. Journal of proteome research. 2010; 9:1323–1329. [PubMed:
20113005]

NIH-PA Author Manuscript
Proteomics Clin Appl. Author manuscript; available in PMC 2015 August 01.

Tian et al.

Page 11

Clinical relevance
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The extracellular matridome plays a critical role in remodeling of the left ventricle (LV)
following myocardial infarction (MI). The aim of this study was to use a glycoproteomics
and mass spectrometry approach to identify glycoproteins in the extracellular matridome
of the infarcted LV, to provide experimental evidence for topological determination. The
information of protein topology is critical for selecting antigen sites and designing drug
targets. The biological reproducibility was also investigated to assess the prevalence of
the identified N-glycosylation sites. The identification of N-glycosylation sites supports
the prediction of the membrane protein topology. Combined, this information may
facilitate the discovery of drug targets and biomarkers for the post-MI patient.
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Figure 1.

(A) Pie chart showing the distribution of glycosites identified per protein. Of the proteins
identified, 59% had 1 glycosite and 41% proteins had ≥2 glycosites. (B) Stacked column
chart showing the prevalence of identified glycopeptides in each of the eight biological
replicates. A total of 36% of the glycosites were identified in all eight samples. (C)
Classification of identified glycopeptides according to SignalP and TNHMM. A total of
77% of the glycopeptides were classified as transmembrane (TM) or secreted proteins.
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Figure 2.
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The glycopeptide identification supports the topology prediction for the β1 integrin, which is
predicted to be a TM protein (with residues 21–728 as the extracellular domain, 729–751 as
the TM helices, and 752–798 as the intracellular domain). There were four N-glycosites
previously identified in other studies (highlighted in green). Five N-glycosites were
identified in this study, and four of the five N-glycosites were not previously reported and
highlighted in yellow.
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Molecular functions and KEGG pathways enriched for the identified glycoproteins, according to Gene
Ontology (GO) analysis. The molecular functions of the identified glycoproteins are ordered by p value, from
lowest to highest value.
Molecular functions enriched for the identified glycoproteins
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Term

P Value

FDR

Count

%

Calcium ion binding

1.8E-35

2.6E-32

111

16.6

Carbohydrate binding

1.4E-28

2.0E-25

62

9.3

Polysaccharide binding

3.3E-24

4.9E-21

38

5.7

Pattern binding

3.3E-24

4.9E-21

38

5.7

Glycosaminoglycan binding

8.0E-23

1.2E-19

35

5.2

Heparin binding

1.8E-19

2.6E-16

28

4.2

Exopeptidase activity

1.6E-13

2.4E-10

21

3.1

Endopeptidase inhibitor activity

1.1E-11

1.5E-08

28

4.2

Metallopeptidase activity

1.3E-11

1.9E-08

30

4.5

Peptidase inhibitor activity

8.8E-11

1.3E-07

28

4.2

Peptidase activity

1.7E-10

2.5E-07

55

8.2

Integrin binding

2.5E-10

3.6E-07

12

1.8

Peptidase activity

2.8E-10

4.1E-07

56

8.4

Carboxypeptidase activity

1.2E-09

1.7E-06

13

1.9

Extracellular matrix structural constituent

2.6E-09

3.7E-06

12

1.8

Serine-type endopeptidase inhibitor activity

2.7E-09

3.9E-06

21

3.1

Transmembrane receptor protein tyrosine kinase activity

5.1E-09

7.4E-06

15

2.2

Enzyme inhibitor activity

7.4E-09

1.1E-05

30

4.5

Growth factor binding

2.1E-08

3.1E-05

16

2.4

Extracellular matrix binding

9.0E-08

1.3E-04

10

1.5

ion binding

9.2E-08

1.3E-04

191

28.6

Cation binding

9.9E-08

1.4E-04

189

28.3

Metalloexopeptidase activity

1.1E-07

1.6E-04

11

1.6

Metallocarboxypeptidase activity

4.4E-07

6.4E-04

9

1.3

Scavenger receptor activity

6.4E-07

9.2E-04

11

1.6

Metal ion binding

1.1E-06

1.5E-03

183

27.4

Sugar binding

1.4E-06

2.1E-03

22

3.3

Protein complex binding

2.8E-06

4.0E-03

14

2.1

KEGG Pathway enriched for identified glycoproteins
Term

P Value

FDR

Count

%

ECM-receptor interaction

1.5E-35

1.8E-32

45

6.7

Lysosome

5.7E-20

6.6E-17

38

5.7

Focal adhesion

2.4E-17

2.8E-14

45

6.7

Cell adhesion molecules

1.1E-16

1.3E-13

39

5.8
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Term

P Value

FDR

Count

%

Complement and coagulation cascades

1.2E-16

1.3E-13

28

4.2

Arrhythmogenic right ventricular cardiomyopathy

1.4E-14

1.7E-11

26

3.9

Hypertrophic cardiomyopathy

3.1E-14

3.6E-11

27

4.0

Hematopoietic cell lineage

2.3E-12

2.6E-09

25

3.7

Dilated cardiomyopathy

2.7E-12

3.1E-09

26

3.9
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Protein description
Integrin alpha-2
Integrin alpha-3
Integrin alpha-4
Integrin alpha-5
Integrin alpha 6
Integrin alpha-8
Integrin alpha-11
Integrin alpha-IIb
Integrin alpha-L
Integrin alpha-V
Integrin beta-1
Integrin beta-2
Integrin beta-3
Integrin beta-5

Accession number

IPI00126077

IPI00126090

IPI00121334

IPI00115976

IPI00227969

IPI00345112

IPI00417168

IPI00315155

IPI00132286

IPI00120245

IPI00132474

IPI00320605

IPI00266264

IPI00229516

Single TM type I

Single TM type I

Single TM type I

Single TM type I

Single TM type I

Single TM type I

Single TM type I

Single TM type I

Single TM type I

Single TM type I

Single TM type II

Single TM type I

Single TM type I

Single TM type I

cellular location

743–816

741–787

726–771

752–798

1013–1044

1109–1163

1013–1033

1165–1188

1034–1062

1038–1073

1026–1053

1008–1039

606–642

1152–1178

Inside

720–742

718–740

703–725

729–751

990–1012

1086–1108

990–1012

1142–1164

1011–1033

1015–1037

1003–1025

985–1007

583–605

1129–1151

Tmhelix

1–719 (1/7)

1–717 (1/6)

1–702 (2/6)

1–728 (5/14)

1–989 (5/13)

1–1085 (2/16)

1–989 (1/5)

1–1141 (4/16)

1–1010 (1/16)

1–1014 (3/8)

1–1002 (5/15)

1–984 (1/12)

1–582 (2/13)

1–1128 (1/9)

Outside

Confirmed topology (identified/predicted glycosites)

The topology of the integrins identified in the ECM-receptor interaction pathway. The numbers represent the amino acid position, with the bracketed
numbers indicating the number of identified/predicted glycosites.
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